Re: Letter of Intent for Clinical Trial Services to be provided by Nordic Bioscience A/S (“NB”) to Radius Health, Inc. (“Radius”)Clinical Trial Services Agreement • December 12th, 2013 • Radius Health, Inc. • Blank checks
Radius and NB are parties to that certain Clinical Trial Services Agreement dated as of the March 29, 2011 (the “CTS Agreement”) and a certain Work Statement NB-3 under the CTS Agreement. Pursuant to Section 2.1 of the CTS Agreement, we have been negotiating the definitive terms of an Amendment No. 1 to Work Statement NB-3 to a Period 2 extension of the clinical study that is the subject of Work Statement NB-3 entitled: BA058-05-005 “An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-00” (the “Study”). Amendment No. 1 to Work Statement NB-3 provides for payment by Radius to NB of both cash and equity compensation in consideration of the services provided by NB, with the equity portion of such compensation to be made pursuant to an Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.
